Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists map metabolic shifts in skin cancer development

NCT ID NCT04389112

Knowledge-focused Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study examined 119 people with precancerous or early skin cancer lesions to understand how cells change as they become cancerous. Researchers took small skin samples and analyzed their metabolism and protein markers. The goal was to learn more about the transition from harmless spots to skin cancer, which could improve early detection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could help identify early warning signs of skin cancer, leading to better detection and prevention strategies.
What could go wrong
This is an observational study, not a treatment trial. The findings may not directly lead to new tests or therapies, and results may not apply to all skin cancer types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

119 people

The number who actually took part.

Started

Feb 2020

Finished

Jun 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Every patient with suspected lesion : * AK, * in situ cSCC, * infiltrative cSSC * cSCC with recurrent disease * cSCC with cutaneous metastases. * Patients 18 years of age or older, * Patients with suspected AK or BCC lesions (in situ, infiltrating or metastatic), * Patient able to sign a consent form, * Patient affiliated with a Social Security system. Exclusion Criteria: * Prior systemic treatment such as checkpoint inhibitors or chemotherapy. * Patients with cSCC or AK localized on visible zone of the face or folds

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Basal cell carcinomas are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

actinic keratosis basal cell carcinoma skin basal cell carcinoma skin squamous cell carcinoma skin squamous cell carcinoma in situ

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Basal cell carcinomas Cutaneous squamous cell carcinoma

Contacts and locations

Locations

  • Hôpital Saint-André - CHU de Bordeaux

    Bordeaux, 33000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.